ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Blackstone invests in Alnylam’s RNAi therapies

by Ryan Cross
April 18, 2020 | APPEARED IN VOLUME 98, ISSUE 15

 

The investment firm Blackstone Life Sciences will provide the RNA interference (RNAi) company Alnylam Pharmaceuticals with up to $2 billion. Half will be in exchange for up to 50% of the royalties Alnylam will receive if its cholesterol-lowering RNAi therapy, inclisiran, is approved. Alnylam licensed inclisiran to The Medicines Company in 2013, and Novartis bought that firm for $9.7 billion in January. Blackstone will also purchase $100 million worth of Alnylam’s stock, provide up to $150 million to develop two additional cardiometabolic RNAi programs, and provide a loan of up to$750 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment